DTaP vaccine - Sanofi-Aventis

Drug Profile

DTaP vaccine - Sanofi-Aventis

Alternative Names: Adacel; COVAXiS; SP 306; Tdap; Triaxis

Latest Information Update: 08 Mar 2016

Price : $50

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 12 Jan 2016 Phase-II clinical trials in Tetanus (In children, Prevention) in Canada (IM)
  • 12 Jan 2016 Phase-II clinical trials in Diphtheria (Prevention, In children) in Canada (IM)
  • 11 May 2015 No recent reports of development identified - Phase-III for Pertussis (In children, Prevention) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top